HomeCompareSRBCF vs EPRT

SRBCF vs EPRT: Dividend Comparison 2026

SRBCF yields 39215.69% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SRBCF wins by $4.252735580217355e+22M in total portfolio value
10 years
SRBCF
SRBCF
● Live price
39215.69%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.252735580217355e+22M
Annual income
$42,315,093,309,418,040,000,000,000,000.00
Full SRBCF calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — SRBCF vs EPRT

📍 SRBCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSRBCFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SRBCF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SRBCF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SRBCF
Annual income on $10K today (after 15% tax)
$3,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$35,967,829,313,005,333,000,000,000,000.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, SRBCF beats the other by $35,967,829,313,005,333,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SRBCF + EPRT for your $10,000?

SRBCF: 50%EPRT: 50%
100% EPRT50/50100% SRBCF
Portfolio after 10yr
$2.1263677901086776e+22M
Annual income
$21,157,546,654,709,020,000,000,000,000.00/yr
Blended yield
99.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

SRBCF
No analyst data
Altman Z
-90.9
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SRBCF buys
0
EPRT buys
0
No recent congressional trades found for SRBCF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSRBCFEPRT
Forward yield39215.69%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$4.252735580217355e+22M$64.3K
Annual income after 10y$42,315,093,309,418,040,000,000,000,000.00$13,170.85
Total dividends collected$4.251340866571809e+22M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: SRBCF vs EPRT ($10,000, DRIP)

YearSRBCF PortfolioSRBCF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$3,932,269$3,921,568.63$11,212$512.01+$3.92MSRBCF
2$1,445,390,825$1,441,183,297.58$12,689$692.09+$1445.38MSRBCF
3$496,629,048,205$495,082,480,022.34$14,521$944.30+$496629.03MSRBCF
4$159,510,701,964,776$158,979,308,883,196.16$16,841$1,302.88+$159510701.95MSRBCF
5$47,892,225,784,148,210$47,721,549,333,045,900.00$19,841$1,821.64+$47892225784.13MSRBCF
6$13,442,027,069,357,296,000$13,390,782,387,768,257,000.00$23,818$2,587.47+$13442027069357.27MSRBCF
7$3,526,928,149,355,307,700,000$3,512,545,180,391,095,400,000.00$29,230$3,744.65+$3526928149355307.50MSRBCF
8$865,104,634,553,737,800,000,000$861,330,821,433,927,700,000,000.00$36,816$5,540.38+$865104634553737856.00MSRBCF
9$198,376,161,453,751,100,000,000,000$197,450,499,494,778,630,000,000,000.00$47,806$8,413.17+$198376161453751107584.00MSRBCF
10$42,527,355,802,173,560,000,000,000,000$42,315,093,309,418,040,000,000,000,000.00$64,324$13,170.85+$4.252735580217355e+22MSRBCF

SRBCF vs EPRT: Complete Analysis 2026

SRBCFStock

Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. Its programs include cosmetic skin lightener and diabetes drug; and other projects include the development of an anti-aging/cell protection library, novel anti-wrinkle compound, and anti-viral program. Sirona Biochem Corp. has a research collaboration agreement with the International Centre for Genetic Engineering and Biotechnology (ICGEB) to develop antiviral library of compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. The company was incorporated in 2006 and is headquartered in Vancouver, Canada.

Full SRBCF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this SRBCF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SRBCF vs SCHDSRBCF vs JEPISRBCF vs OSRBCF vs KOSRBCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.